Previous Close | 128.20 |
Open | N/A |
Bid | 120.00 |
Ask | 125.00 |
Strike | 350.00 |
Expire Date | 2025-01-17 |
Day's Range | 128.20 - 128.20 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Strong Margin Execution and Cash Flow Highlight Second Quarter Performance
Becton Dickinson raised its annual profit forecast and beat second-quarter profit estimates on Thursday, as the group banks on strong demand for its surgical equipment and syringes. Medical technology firms like Becton, Boston Scientific and Abbott Laboratories are benefiting from a boost in demand as more people, especially older patients, undergo surgeries that were put on hold during the pandemic. The company's biggest unit, which makes devices to administer drugs, reported quarterly sales of $2.45 billion, in line with analysts' expectations, according to LSEG data.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its second quarter of fiscal 2024, which ended March 31, 2024.